• Beam Therapeutics' BEAM-101, targeting sickle cell disease, has completed dosing in the sentinel cohort of its Phase 1/2 BEACON trial, with initial data expected at the ASH Annual Meeting.
• The company's BEAM-302 for Alpha-1 Antitrypsin Deficiency has begun dosing patients in its Phase 1/2 trial, with initial data anticipated in the second half of 2025.
• Beam has made advancements in manufacturing, showcasing an automated CD34+ cell process that increases capacity threefold while improving consistency for BEAM-101.
• With a strong cash position of $1.1 billion, Beam is financially secure into 2027, enabling continued investment in its research and development programs.